Skip to content
ModernDoc
Get the app
The research library
COVID-19 / SPECIALTY RESEARCH

TherapeuticsIn perspective.

The key COVID-19 findings in therapeutics, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.

INSIDE THIS MONITOR
36cited sources
23available findings

Study findings updated

AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.

THE SHORT VERSION

What’s worth knowing.

The key findings, what they mean, and the context that matters.

THE HEADLINE TAKEAWAY

No primary day-90 benefit was established for nirmatrelvir-ritonavir

For established Long COVID, neither the 15-day nor 25-day regimen established a benefit versus placebo on primary patient-reported autonomic, cognitive, or exercise outcomes.

The USA trial was randomized, double-blind, and placebo-controlled. Across all 963 participants, 42 (4%) experienced 52 serious adverse events, and there were no deaths; events were not reported as a between-group comparison.

See the evidence

Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

-0.1% (p=0.99)
95% CI: -12.5 to 12.3

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

3.2% (p=0.65)
95% CI: -10.4 to 16.8

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

-2.2% (p=0.74)
95% CI: -15.5 to 11.1

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

-7.8% (p=0.19)
95% CI: -19.5 to 3.8

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

-6.4% (p=0.30)
95% CI: -18.5 to 5.7

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

0.9% (p=0.88)
95% CI: -11.4 to 13.2

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab

Serious adverse events across all study participants over the course of the trial; this was not reported as a between-group comparison

42 of 963 participants (4%; 52 serious adverse events), with no deaths

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [36]Original source in a new tab
02

Acute nirmatrelvir-ritonavir reduced Long COVID risk

40%lower relative risk

When used for acute COVID-19, nirmatrelvir-ritonavir lowered the relative risk of Long COVID at 3 months by 40% versus placebo.

In the randomized, double-blind PANORAMIC Norway trial, Long COVID incidence at 3 months was 26% with nirmatrelvir-ritonavir and 43% with placebo. This addresses prevention, not treatment of established Long COVID.

See the evidence

40% lower relative risk, calculated from RR 0.60. This is not an absolute percentage-point difference.

Risk of long COVID at 3 months with nirmatrelvir-ritonavir vs placebo for acute COVID-19 treatment

RR 0.60
95% CI 0.37-0.98

Oppegaard, Oddvar et al.. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [32]Original source in a new tab

Long COVID incidence at 3 months in nirmatrelvir-ritonavir group

26%

Oppegaard, Oddvar et al.. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [32]Original source in a new tab

Long COVID incidence at 3 months in placebo group

43%

Oppegaard, Oddvar et al.. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.. The Lancet. Infectious diseases. 2026.

Added

Citation [32]Original source in a new tab
03

Cognitive rehabilitation improved goal attainment

Among people with Long COVID-related cognitive impairment, cognitive rehabilitation improved goal attainment versus treatment as usual at 3 months. Sustained improvement was reported at 6 months.

This was a randomized clinical trial. The comparator for the 6-month result is not identified in this summary, and the measured outcome was goal attainment rather than every cognitive outcome.

See the evidence

Goal attainment improvement with cognitive rehabilitation vs treatment as usual at 3 months

Cohen d = 1.57
95% CI: 2.03-3.73

Vanova, Martina et al.. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.. JAMA network open. 2026.

Citation [31]Original source in a new tab

Sustained goal attainment improvement with cognitive rehabilitation at 6 months

Cohen d = 0.91
95% CI: 0.86-2.57

Vanova, Martina et al.. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.. JAMA network open. 2026.

Citation [31]Original source in a new tab
04

VSL#3® improved fatigue response after 4 weeks

68% vs 35.7%; p=0.019

After 4 weeks, 68% of patients receiving VSL#3® were fatigue responders versus 35.7% receiving placebo.

This randomized placebo-controlled trial enrolled patients with Long COVID and clinically relevant fatigue. The fatigue-responder definition is not available in this summary.

See the evidence

Fatigue responder proportion after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

68% vs 35.7%; p=0.019

Amoroso, Chiara et al.. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.. British journal of biomedical science. 2026.

Added

Citation [35]Original source in a new tab

Reduction in Chalder Fatigue Scale score after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

24.24% vs 6.06%; p=0.037

Amoroso, Chiara et al.. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.. British journal of biomedical science. 2026.

Added

Citation [35]Original source in a new tab
05

Heart pumping results were uncertain with losartan plus prednisolone

After 16 weeks, losartan plus prednisolone did not establish a difference from placebo in the primary unadjusted analysis of left-ventricular ejection fraction, a measure of heart pumping. A supportive baseline-adjusted analysis found a greater increase with treatment.

The randomized, double-blind trial was limited to post-COVID syndrome with inflammatory cardiac involvement. The discordant primary and supportive analyses make the result uncertain.

See the evidence

Change in LV ejection fraction after 16 weeks of losartan plus prednisolone versus placebo in post-COVID syndrome with inflammatory cardiac involvement; the primary unadjusted analysis was neutral despite a positive supportive baseline-adjusted analysis.

Between-group difference 0.74 percentage points (p=0.10); supportive baseline-adjusted ANCOVA difference 0.99 percentage points (p=0.021)
95% CI: -0.14 to 1.62; supportive ANCOVA 95% CI: 0.15-1.83

Puntmann, Valentina O et al.. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.. Nature communications. 2026.

Added

Citation [34]Original source in a new tab
06

Vaccination was linked to lower Long COVID odds

A systematic review associated vaccination with lower odds of Long COVID. The reference group is not identified in this summary, so the comparative magnitude is not shown.

The vaccine formulation and timing are not available in this summary. The outcome concerns Long COVID occurrence, not response of established symptoms to therapy.

See the evidence

Vaccination Protection

-50%
OR 0.5 (95% CI: 0.4-0.6)

Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385.

Citation [25]Original source in a new tab

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

THE RESEARCH, AS IT ARRIVES

Latest studies.

The newest findings added to this collection.
The learning from each, already distilled.

  1. STUDY 01Findings added
    Therapeutics
    TL;DR

    No primary day-90 benefit was established for either regimen

    The 15-day and 25-day nirmatrelvir-ritonavir regimens did not establish a benefit versus placebo on primary autonomic, cognitive, or exercise patient-reported outcomes.

    The USA trial was randomized, double-blind, and placebo-controlled in people with Long COVID. These null findings do not prove that the regimens are equal to placebo.

    Serious adverse events were reported only as an overall total

    Across all 963 participants, 42 (4%) experienced 52 serious adverse events, with no deaths.

    The count covers the course of the trial and was not reported as a between-group comparison, so it cannot show whether either regimen differed from placebo in serious-event risk.

    Study details & original results

    Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

    Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

    -0.1% (p=0.99)
    95% CI: -12.5 to 12.3

    Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

    3.2% (p=0.65)
    95% CI: -10.4 to 16.8

    Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

    -2.2% (p=0.74)
    95% CI: -15.5 to 11.1

    Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

    -7.8% (p=0.19)
    95% CI: -19.5 to 3.8

    Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

    -6.4% (p=0.30)
    95% CI: -18.5 to 5.7

    Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

    0.9% (p=0.88)
    95% CI: -11.4 to 13.2

    Citation in Therapeutics

    Serious adverse events across all study participants over the course of the trial; this was not reported as a between-group comparison

    42 of 963 participants (4%; 52 serious adverse events), with no deaths

    Citation in Therapeutics
    2 key learningsRead original study in a new tab
  2. STUDY 02Findings added
    Therapeutics
    TL;DR

    VSL#3® improved fatigue response after 4 weeks

    68% vs 35.7%; p=0.019

    After 4 weeks, 68% of patients receiving VSL#3® were fatigue responders versus 35.7% receiving placebo.

    The randomized placebo-controlled trial involved patients with Long COVID and clinically relevant fatigue. It also reported a greater Chalder Fatigue Scale score reduction with VSL#3® than placebo, but the responder definition is unavailable here.

    Study details & original results

    Amoroso, Chiara et al.. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.. British journal of biomedical science. 2026.

    Fatigue responder proportion after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

    68% vs 35.7%; p=0.019

    Reduction in Chalder Fatigue Scale score after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

    24.24% vs 6.06%; p=0.037

    Citation in Therapeutics
    One key learningRead original study in a new tab
  3. STUDY 03Findings added
    Therapeutics
    TL;DR

    Heart pumping results were uncertain with losartan plus prednisolone

    After 16 weeks, losartan plus prednisolone did not establish a difference from placebo in the primary unadjusted analysis of left-ventricular ejection fraction, a measure of heart pumping. A supportive baseline-adjusted analysis found a greater increase with treatment.

    This randomized, double-blind trial was restricted to post-COVID syndrome with inflammatory cardiac involvement. Its primary and supportive analyses gave discordant conclusions.

    Study details & original results

    Puntmann, Valentina O et al.. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.. Nature communications. 2026.

    Change in LV ejection fraction after 16 weeks of losartan plus prednisolone versus placebo in post-COVID syndrome with inflammatory cardiac involvement; the primary unadjusted analysis was neutral despite a positive supportive baseline-adjusted analysis.

    Between-group difference 0.74 percentage points (p=0.10); supportive baseline-adjusted ANCOVA difference 0.99 percentage points (p=0.021)
    95% CI: -0.14 to 1.62; supportive ANCOVA 95% CI: 0.15-1.83

    Citation in Therapeutics
    One key learningRead original study in a new tab
  4. STUDY 04Findings added
    Therapeutics
    TL;DR

    SSRI prescription was linked to lower symptom-category risks

    Among patients with depression, SSRI prescription during acute COVID-19 was associated with lower adjusted risks of general health-related, skin-related, gastrointestinal, and headache-related Long COVID symptoms.

    The source is a preprint. Its reference group is not identified in this summary, so the adjusted risk-ratio magnitudes cannot be interpreted as a named comparison.

    Study details & original results

    Butzin-Dozier, Zachary et al.. SSRI prescription during acute COVID-19 and risk of Long COVID symptoms and conditions among patients with depression.. medRxiv : the preprint server for health sciences. 2026.

    General health-related Long COVID symptoms with SSRI prescription during acute COVID-19

    aRR 0.91
    95% CI 0.88, 0.95

    Skin-related Long COVID symptoms with SSRI prescription during acute COVID-19

    aRR 0.92
    95% CI 0.87, 0.98

    Gastrointestinal Long COVID symptoms with SSRI prescription during acute COVID-19

    aRR 0.95
    95% CI 0.92, 0.97

    Headache-related Long COVID symptoms with SSRI prescription during acute COVID-19

    aRR 0.96
    95% CI 0.92, 0.99

    Citation in Therapeutics
    One key learningRead original study in a new tab
4 of 5 study updates

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.

WHEN YOU WANT TO GO DEEPER
See all 23 findingsOriginal results, comparisons and study details.
10 of 10 source groupsFindings stay together with their study.
SOURCE 367 findings

Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

Read original source in a new tabView citation [36]

Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

Added
3.2% (p=0.65)95% CI: -10.4 to 16.8Source [36]

Adjusted difference versus placebo in the day-90 cognitive-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

Added
-2.2% (p=0.74)95% CI: -15.5 to 11.1Source [36]
All 7 findings from this source

Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

Added
-6.4% (p=0.30)95% CI: -18.5 to 5.7Source [36]

Adjusted difference versus placebo in the day-90 autonomic-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

Added
-0.1% (p=0.99)95% CI: -12.5 to 12.3Source [36]

Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 25-day nirmatrelvir-ritonavir regimen

Added
-7.8% (p=0.19)95% CI: -19.5 to 3.8Source [36]

Adjusted difference versus placebo in the day-90 exercise-phenotype primary patient-reported outcome with the 15-day nirmatrelvir-ritonavir regimen

Added
0.9% (p=0.88)95% CI: -11.4 to 13.2Source [36]

Serious adverse events across all study participants over the course of the trial; this was not reported as a between-group comparison

Added
42 of 963 participants (4%; 52 serious adverse events), with no deathsSource [36]
SOURCE 352 findings

Amoroso, Chiara et al.. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.. British journal of biomedical science. 2026.

Read original source in a new tabView citation [35]

Reduction in Chalder Fatigue Scale score after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

Added
24.24% vs 6.06%; p=0.037Source [35]

Fatigue responder proportion after 4 weeks of VSL#3® versus placebo in patients with long COVID and clinically relevant fatigue

Added
68% vs 35.7%; p=0.019Source [35]
SOURCE 341 finding

Puntmann, Valentina O et al.. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.. Nature communications. 2026.

Read original source in a new tabView citation [34]

Change in LV ejection fraction after 16 weeks of losartan plus prednisolone versus placebo in post-COVID syndrome with inflammatory cardiac involvement; the primary unadjusted analysis was neutral despite a positive supportive baseline-adjusted analysis.

Added
Between-group difference 0.74 percentage points (p=0.10); supportive baseline-adjusted ANCOVA difference 0.99 percentage points (p=0.021)95% CI: -0.14 to 1.62; supportive ANCOVA 95% CI: 0.15-1.83Source [34]
SOURCE 334 findings

Butzin-Dozier, Zachary et al.. SSRI prescription during acute COVID-19 and risk of Long COVID symptoms and conditions among patients with depression.. medRxiv : the preprint server for health sciences. 2026.

Read original source in a new tabView citation [33]

Gastrointestinal Long COVID symptoms with SSRI prescription during acute COVID-19

Added
aRR 0.9595% CI 0.92, 0.97Source [33]

General health-related Long COVID symptoms with SSRI prescription during acute COVID-19

Added
aRR 0.9195% CI 0.88, 0.95Source [33]
All 4 findings from this source

Headache-related Long COVID symptoms with SSRI prescription during acute COVID-19

Added
aRR 0.9695% CI 0.92, 0.99Source [33]

Skin-related Long COVID symptoms with SSRI prescription during acute COVID-19

Added
aRR 0.9295% CI 0.87, 0.98Source [33]
SOURCE 323 findings

Oppegaard, Oddvar et al.. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.. The Lancet. Infectious diseases. 2026.

Read original source in a new tabView citation [32]

Risk of long COVID at 3 months with nirmatrelvir-ritonavir vs placebo for acute COVID-19 treatment

Added
RR 0.6095% CI 0.37-0.98Source [32]

Long COVID incidence at 3 months in nirmatrelvir-ritonavir group

Added
26%Source [32]
All 3 findings from this source

Long COVID incidence at 3 months in placebo group

Added
43%Source [32]
SOURCE 051 finding

RECOVER Consortium. RECOVER-VITAL: Paxlovid for Post-Acute Sequelae of SARS-CoV-2 Infection. N Engl J Med. 2024.

Original source link unavailableView citation [5]

Paxlovid for Long COVID

No benefitp=0.38 vs placebo at 10 weeksSource [5]
SOURCE 151 finding

O'Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.

Read original source in a new tabView citation [15]

LDN Response Rate

30-50%Fatigue improvement in observational studiesSource [15]
SOURCE 251 finding

Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385.

Read original source in a new tabView citation [25]

Vaccination Protection

-50%OR 0.5 (95% CI: 0.4-0.6)Source [25]
SOURCE 312 findings

Vanova, Martina et al.. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.. JAMA network open. 2026.

Read original source in a new tabView citation [31]

Goal attainment improvement with cognitive rehabilitation vs treatment as usual at 3 months

Cohen d = 1.5795% CI: 2.03-3.73Source [31]

Sustained goal attainment improvement with cognitive rehabilitation at 6 months

Cohen d = 0.9195% CI: 0.86-2.57Source [31]
Browse the 36 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.

    Open original source in a new tab
  2. [2]

    Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593-1607.

    Open original source in a new tab
  3. [3]

    Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615.

    Open original source in a new tab
  4. [4]

    Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452-461.

    Open original source in a new tab
  5. [5]

    RECOVER Consortium. RECOVER-VITAL: Paxlovid for Post-Acute Sequelae of SARS-CoV-2 Infection. N Engl J Med. 2024.

    Original source link unavailable
  6. [6]

    STIMULATE-ICP Collaborative Group. Rivaroxaban, atorvastatin, and famotidine for post-COVID-19 condition: the STIMULATE-ICP randomised trial. JAMA. 2024.

    Original source link unavailable
  7. [7]

    Stanford STOP-PASC Trial. Extended Paxlovid treatment for Long COVID. Preliminary results presented at CROI 2024.

    Original source link unavailable
  8. [8]

    PANORAMIC Trial Investigators. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC). Lancet. 2023;401(10373):281-293.

    Original source link unavailable
  9. [9]

    Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172.

    Open original source in a new tab
  10. [10]

    Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.

    Open original source in a new tab
  11. [11]

    Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis. 2023;76(3):e487-e490.

    Open original source in a new tab
  12. [12]

    Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20.

    Open original source in a new tab
  13. [13]

    Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405.

    Open original source in a new tab
  14. [14]

    Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263-2264.

    Open original source in a new tab
  15. [15]

    O'Kelly B, Vidal L, McHugh T, et al. Safety and efficacy of low dose naltrexone in a long COVID cohort; an interventional pre-post study. Brain Behav Immun Health. 2022;24:100485.

    Open original source in a new tab
  16. [16]

    Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252.

    Open original source in a new tab
  17. [17]

    Liu TH, Ho CH, Chen DTL, et al. Effect of nirmatrelvir/ritonavir treatment during acute COVID-19 on the development of long COVID. JAMA Intern Med. 2023.

    Original source link unavailable
  18. [18]

    PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK. Lancet Respir Med. 2022;10(8):761-775.

    Open original source in a new tab
  19. [19]

    Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID). Lancet Respir Med. 2021;9(11):1275-1287.

    Open original source in a new tab
  20. [20]

    Hampshire A, Chatfield DA, MPhil AM, et al. Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort. eClinicalMedicine. 2022;47:101417.

    Open original source in a new tab
  21. [21]

    World Health Organization. Clinical management of COVID-19: Living guideline, 18 August 2023. WHO/2019-nCoV/clinical/2023.2

    Original source link unavailable
  22. [22]

    National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Updated 2022.

    Original source link unavailable
  23. [23]

    Centers for Disease Control and Prevention. Long COVID or Post-COVID Conditions. Updated 2024.

    Original source link unavailable
  24. [24]

    American Academy of Physical Medicine and Rehabilitation (AAPM&R). PASC Multi-Disciplinary Collaborative Consensus Guidance Statements. 2021-2024.

    Original source link unavailable
  25. [25]

    Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1):e000385.

    Open original source in a new tab
  26. [26]

    Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023;183(6):554-564.

    Open original source in a new tab
  27. [27]

    Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT). Lancet Infect Dis. 2023;23(10):1119-1129.

    Original source link unavailable
  28. [28]

    Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43(4):268-270.

    Open original source in a new tab
  29. [29]

    Choutka J, Jansari V, Engber T, Zack M. Unexplained post-acute infection syndromes. Nat Med. 2022;28(5):911-923.

    Open original source in a new tab
  30. [30]

    Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med (Lausanne). 2023;10:1187163.

    Open original source in a new tab
  31. [31]

    Vanova, Martina et al.. Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial.. JAMA network open. 2026.

    Open original source in a new tab
  32. [32]

    Oppegaard, Oddvar et al.. Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.. The Lancet. Infectious diseases. 2026.

    Open original source in a new tab
  33. [33]

    Butzin-Dozier, Zachary et al.. SSRI prescription during acute COVID-19 and risk of Long COVID symptoms and conditions among patients with depression.. medRxiv : the preprint server for health sciences. 2026.

    Open original source in a new tab
  34. [34]

    Puntmann, Valentina O et al.. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial.. Nature communications. 2026.

    Open original source in a new tab
  35. [35]

    Amoroso, Chiara et al.. VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial.. British journal of biomedical science. 2026.

    Open original source in a new tab
  36. [36]

    Baden, Lindsey R et al.. Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.. The Lancet. Infectious diseases. 2026.

    Open original source in a new tab
ABOUT THIS MONITOR

Understanding includes the limits.

This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.

Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.

How this monitor is made Report a correction
KEEP YOUR QUESTIONS CLOSE

A little more understanding.
Wherever you are.

Explore the ModernDoc app